Navigation Links
The Neuropathy Association's Scientific Research Grants Focus: Autoimmune and Chemotherapy-Induced Neuropathies
Date:11/10/2008

NEW YORK, Nov. 10 /PRNewswire-USNewswire/ -- The Neuropathy Association has announced two awardees for its annual Scientific Research Grants Program.

Every year, The Neuropathy Association--a national patient-based non-profit organization dedicated to finding a cure for neuropathy--awards two scientific research grants, each for $80,000 over a two-year period.

This year's grant recipients--Gary J. Bennett, Ph.D. of McGill University (Quebec, Canada) and Helene Bour-Jordan, Ph.D. and co-principal investigator, Mark S. Anderson, M.D., Ph.D. of the University of California, San Francisco (UCSF) Diabetes Center--were chosen from eleven applicants involved in neuropathy research at medical institutions across North America.

Dr. Bennett's proposal, Mechanism of Paclitaxel-Evoked Peripheral Neuropathy, is based on data suggesting that paclitaxel (Taxol(R)) causes neuropathy by a novel and previously unrecognized mechanism. Paclitaxel is used by tens of thousands of patients as a first-line drug in the treatment of ovarian, breast and non-small cell lung cancer. The neuropathy, a serious side-effect of paclitaxel, can be severe---and often painful---thus preventing or limiting the use of the drug as an effective chemotherapeutic and leading to a decline in the patient's quality of life.

Dr. Bennett adds, "Preventing and controlling the neuropathy resulting from paclitaxel will, in turn, allow us to administer larger doses to more effectively kill cancer cells and save lives."

With their proposal, Identification of Neural Autoantigens in Autoimmune Peripheral Neuropathy, Drs. Bour-Jordan and Anderson hope to identify proteins of the peripheral nervous system that are targeted by the immune system in autoimmune neuropathy.

Dr. Bour-Jordan explains, "Autoantibodies in tissue-specific autoimmune diseases are excellent indicators of disease and are instrumental in identifying major autoantigens that are now used in clinical trials for several autoimmune disorders, including type 1 diabetes, multiple sclerosis and rheumatoid arthritis."

Ronnie Chalif, the Association's president affirms, "Finding a cure for neuropathy requires that we continue building upon our strategic research initiatives by making targeted investments in neuropathy research."

About Peripheral Neuropathy

Peripheral neuropathy is one of the most common diseases affecting approximately 20 million Americans.

Neuropathy results from injury to the peripheral nerves---the motor, sensory and autonomic nerves connecting the spinal cord to the muscles, skin, blood vessels and internal organs. It usually affects the hands and feet, causing weakness, numbness, lack of coordination or pain.

Approximately 30% of neuropathies are "idiopathic," meaning of an unknown cause; 30% are caused by diabetes. Other causes include autoimmune disorders, tumors, heredity, nutritional deficiencies, infections, trauma, and drugs or toxins.

About The Neuropathy Association

The Neuropathy Association(R), the leading national patient-based nonprofit organization, was established in 1995 by people with neuropathy and their families and friends to help those who suffer from disorders of the peripheral nerves. Now a national organization with over 50,000 members and supporters, 12 Association-designated neuropathy centers and 130 support groups, the Association's mission is to provide patient support and education, advocate for patients' interests, and find a cure for neuropathy.

For more information about peripheral neuropathy and The Neuropathy Association, visit http://www.neuropathy.org.


'/>"/>
SOURCE The Neuropathy Association
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ReBuilder Medical Technologies, Inc. Contracts with ETS to Manufacture the Newest Version of its ReBuilder Neuropathy Treatment Device; Expects Sales to Increase 30%
2. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
3. Current and Emerging Therapies Have No Advantage Over Pfizers Lyrica in Their Effect on Patients Quality of Life in the Treatment of Diabetic Neuropathy
4. The Neuropathy Association Featured on NBCs Today Show as Part of National Neuropathy Week
5. The cause of all hereditary sensory and autonomic neuropathy type II cases has been established
6. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
7. Salugen to Present Research on Generational Associations of Reward Deficiency Syndrome at XVth World Congress on Psychiatric Genetics
8. Pharmacist Associations Partner to Increase the Voice of Pharmacy
9. Major Associations Band Together to Urge Congressional Action on Tobacco Legislation
10. American Heart Associations Announces Call for Entries for Howard L. Lewis Achievement Award
11. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... , ... The Waismann Method® is providing a faster, safer, and ... victim to America’s opioid epidemic. Now, opiate dependent individuals can be treated in a ... the shame, stigma, and harmful labeling believed to prevent many of these ...
(Date:2/22/2017)... ... February 22, 2017 , ... VitreosHealth ... each Medicare Advantage member’s risk, identify any gaps-in-coding, as well as gaps-in-care ... transform the HCC Risk Adjustment process from a typical fragmented process to ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This ... instant absorption from the mouth into the bloodstream. Far outpacing the ...
(Date:2/22/2017)... ... February 22, 2017 , ... Becker’s Spine Review, the ... featuring Michigan neurosurgeon Jay Jagannathan, M.D., as a “Spine Surgeon to Know.” ... neurosurgeons in Michigan performing minimally invasive back surgery that often results in less ...
(Date:2/22/2017)... ... February 22, 2017 , ... The SeniorCare Investor will host an important webinar— ... 23, 2017, at 1:00 PM ET. A recording of the webinar will also be ... Series. , If you want to find out what really happened in the seniors ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... Feb. 22, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE ... the quarter and full fiscal year ended December 31, 2016. ... ... Company,s audited financial statements and management discussion and analysis for ... been filed on SEDAR and are available at www.sedar.com ...
(Date:2/22/2017)... Feb. 22, 2017 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... its Fourth Quarter 2016 investor conference call and webcast at ... The call will cover an update on Merrimack,s recent ... full year 2016 financial results. A press release detailing the ... the morning of Wednesday, March 1. Investors and the general ...
(Date:2/22/2017)... NEW YORK , Feb. 22, 2017 ... non-small cell lung cancer partnering deals and agreements entered ... the full report: http://www.reportlinker.com/p03605668-summary/view-report.html Description The ... since 2010 report provides understanding and access to partnering ... healthcare companies. - Trends in partnering deals ...
Breaking Medicine Technology: